Deal Library / Pharma BD Deal Intelligence

Eli Lilly and Company — Pharma Deals

The Pharma Closeout tracks 63 deals, $103.2B in disclosed deal value, 26 with a post-close Outcome Score for Eli Lilly and Company.

Median Critic Score: 75  ·  Median Outcome Score: 61

Best outcome: Eli Lilly and Company / Boehringer Ingelheim GmbH (89)  ·  Weakest outcome: Eli Lilly and Company / Alnara Pharmaceuticals (13)

All 63 deals

• Eli Lilly and Company / Boehringer Ingelheim GmbH — 2011 · $444M · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Loxo Oncology, Inc. — 2019 · $8.0B · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Applied Molecular Evolution Inc. — 2003 · $400M · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / ICOS Corporation — 2006 · $2.3B · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Novartis Animal Health — 2014 · $5.4B · Largely worked — most objectives met.
• Eli Lilly and Company / Incyte Corporation — 2009 · $755M · Largely worked — most objectives met.
• Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. — 2026 · $1.3B · Largely worked — most objectives met.
• Eli Lilly and Company / Scorpion Therapeutics — 2025 · $2.5B · Largely worked — most objectives met.
• Eli Lilly and Company / Versanis Bio — 2023 · $1.9B · Largely worked — most objectives met.
• Eli Lilly and Company / Ascidian Therapeutics, Inc. — 2026 · $1.9B · Largely worked — most objectives met.
• Eli Lilly and Company / Morphic Holdings — 2024 · $3.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Point Biopharma — 2023 · $1.4B · Largely worked — most objectives met.
• Eli Lilly and Company / AtaiBeckley Inc. — 2026 · $3.8B · Largely worked — most objectives met.
• Eli Lilly and Company / ImClone Systems Incorporated — 2008 · $6.5B · Largely worked — most objectives met.
• Eli Lilly and Company / AC Immune SA — 2017 · $2.0B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $3.1B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / CoLucid Pharmaceuticals — 2017 · $960M · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / AlzeCure Pharma AB — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Sangamo Therapeutics, Inc. — 2026 · $50M · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Avid Radiopharmaceuticals, Inc. — 2010 · $800M · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / 4E Therapeutics, Inc. — 2026 · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / DICE Therapeutics Inc. — 2023 · $2.4B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Prevail Therapeutics — 2020 · $1.0B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2018 · $1.8B · Underwhelmed — fell short of the thesis.
• Eli Lilly and Company / ARMO BioSciences Inc. — 2018 · $1.6B · Did not work — the deal failed to deliver.
• Eli Lilly and Company / Alnara Pharmaceuticals — 2010 · $380M · Did not work — the deal failed to deliver.
• Eli Lilly and Company / Vaccine Company, Inc. — 2026 · $1.6B
• Eli Lilly and Company / Kelonia Therapeutics, Inc. — 2026 · $7.0B
• Eli Lilly and Company / Profluent Bio — 2026 · $2.2B
• Eli Lilly and Company / Curevo Vaccine, Inc. — 2026 · $1.5B
• Eli Lilly and Company / LimmaTech Biologics AG — 2026 · $780M
• Eli Lilly and Company / Engage Biologics, Inc. — 2026 · $202M
• Eli Lilly and Company / Centessa Pharmaceuticals plc — 2026 · $7.8B
• Eli Lilly and Company / Ajax Therapeutics, Inc. — 2026 · $2.3B
• Eli Lilly and Company / CrossBridge Bio, Inc. — 2026 · $300M
• Eli Lilly and Company / Orna Therapeutics, Inc. — 2026 · $2.4B
• Eli Lilly and Company / Ventyx Biosciences, Inc. — 2026 · $1.2B
• Eli Lilly and Company / Verve Therapeutics, Inc. — 2025 · $1.3B
• Eli Lilly and Company / Adverum Biotechnologies, Inc. — 2025 · $261M
• Eli Lilly and Company / Radionetics Oncology Inc. — 2024 · $1.1B
• Eli Lilly and Company / HAYA Therapeutics SA — 2024 · $1.0B
• Eli Lilly and Company / Beam Therapeutics Inc. — 2023 · $600M
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2023 · $310M
• Eli Lilly and Company / Mablink Bioscience SAS — 2023 · $250M
• Eli Lilly and Company / Nimbus Therapeutics LLC — 2022 · $496M
• Eli Lilly and Company / Sosei Group Corp. (Sosei Heptares) — 2022 · $730M
• Eli Lilly and Company / Akouos Inc. — 2022 · $610M
• Eli Lilly and Company / Protomer Technologies — 2021 · $1.0B
• Eli Lilly and Company / Foghorn Therapeutics Inc. — 2021 · $1.7B
• Eli Lilly and Company / Kumquat Biosciences, Inc. — 2021 · $2.1B
• Eli Lilly and Company / Rigel Pharmaceuticals, Inc. — 2021 · $960M
• Eli Lilly and Company / Asahi Kasei Pharma — 2021 · $230M
• Eli Lilly and Company / Merus N.V. — 2021 · $1.7B
• Eli Lilly and Company / Dermira Inc. — 2020 · $1.1B
• Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd. — 2020 · $255M
• Eli Lilly and Company / AC Immune SA — 2019 · $1.9B
• Eli Lilly and Company / AurKa Pharma Inc. — 2019 · $575M
• Eli Lilly and Company / Centrexion Therapeutics Corporation — 2019 · $575M
• Eli Lilly and Company / ImmuNext Inc. (anti-VISTA license) — 2019 · $350M
• Eli Lilly and Company / Hanmi Pharmaceutical Co., Ltd. (HM71224 program) — 2015 · $690M
• Eli Lilly and Company / Immunocore Limited — 2014 · $365M
• Eli Lilly and Company / Adocia SA — 2014 · $570M
• Eli Lilly and Company / Acrux Limited (AXIRON license) — 2010 · $335M

← Deal Library  ·  Interactive search  ·  How we score deals